Neurofibromatosis type 1
- 23 February 2017
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Disease Primers
- Vol. 3 (1), nrdp20174
- https://doi.org/10.1038/nrdp.2017.4
Abstract
Neurofibromatosis type 1 is a complex autosomal dominant disorder caused by germline mutations in the NF1 tumour suppressor gene. Nearly all individuals with neurofibromatosis type 1 develop pigmentary lesions (café-au-lait macules, skinfold freckling and Lisch nodules) and dermal neurofibromas. Some individuals develop skeletal abnormalities (scoliosis, tibial pseudarthrosis and orbital dysplasia), brain tumours (optic pathway gliomas and glioblastoma), peripheral nerve tumours (spinal neurofibromas, plexiform neurofibromas and malignant peripheral nerve sheath tumours), learning disabilities, attention deficits, and social and behavioural problems, which can negatively affect quality of life. With the identification of NF1 and the generation of accurate preclinical mouse strains that model some of these clinical features, therapies that target the underlying molecular and cellular pathophysiology for neurofibromatosis type 1 are becoming available. Although no single treatment exists, current clinical management strategies include early detection of disease phenotypes (risk assessment) and biologically targeted therapies. Similarly, new medical and behavioural interventions are emerging to improve the quality of life of patients. Although considerable progress has been made in understanding this condition, numerous challenges remain; a collaborative and interdisciplinary approach is required to manage individuals with neurofibromatosis type1 and to develop effective treatments.Keywords
This publication has 102 references indexed in Scilit:
- Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989European Journal of Human Genetics, 2011
- The Development of Cutaneous NeurofibromasThe American Journal of Pathology, 2011
- Preclincial testing of Sorafenib and RAD001 in the Nfflox/flox;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imagingPediatric Blood & Cancer, 2011
- Cell of Origin and Microenvironment Contribution for NF1-Associated Dermal NeurofibromasCell Stem Cell, 2009
- Neurofibromin Regulation of ERK Signaling Modulates GABA Release and LearningCell, 2008
- Nf1-Dependent Tumors Require a Microenvironment Containing Nf1+/−- and c-kit-Dependent Bone MarrowCell, 2008
- Effect of Simvastatin on Cognitive Functioning in Children With Neurofibromatosis Type 1Jama-Journal Of The American Medical Association, 2008
- The Loss of Nf1 Transiently Promotes Self-Renewal but Not Tumorigenesis by Neural Crest Stem CellsCancer Cell, 2008
- Plexiform and Dermal Neurofibromas and Pigmentation Are Caused by Nf1 Loss in Desert Hedgehog-Expressing CellsCancer Cell, 2008
- ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiaeCell Metabolism, 2006